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Abstract
Chloroquine (CQ) and hydroxychloroquine (HCQ) are well-known 4-aminoquinoline antimalarial agents. Scientific evidence also supports 
the use of CQ and HCQ in the treatment of cancer. Overall, preclinical studies support CQ and HCQ use in anti-cancer therapy, especially 
in combination with conventional anti-cancer treatments since they are able to sensitise tumour cells to a variety of drugs, potentiating the 
therapeutic activity. Thus far, clinical results are mostly in favour of the repurposing of CQ. However, over 30 clinical studies are still evalu-
ating the activity of both CQ and HCQ in different cancer types and in combination with various standard treatments. Interestingly, CQ and 
HCQ exert effects both on cancer cells and on the tumour microenvironment. In addition to inhibition of the autophagic flux, which is the 
most studied anti-cancer effect of CQ and HCQ, these drugs affect the Toll-like receptor 9, p53 and CXCR4-CXCL12 pathway in cancer 
cells. In the tumour stroma, CQ was shown to affect the tumour vasculature, cancer-associated fibroblasts and the immune system. The 
evidence reviewed in this paper indicates that both CQ and HCQ deserve further clinical investigations in several cancer types. Special 
attention about the drug (CQ versus HCQ), the dose and the schedule of administration should be taken in the design of new trials.
Keywords: Repurposing Drugs in Oncology (ReDO) project, drug repositioning, chloroquine (CQ), hydroxychloroquine (HCQ), neoplasms, 
antineoplastic agents, anti-malarial agents.
Cl
in
ic
al
 S
tu
dy
 2 www.ecancer.org
ecancer 2017, 11:781
Introduction
Chloroquine (CQ) and hydroxychloroquine (HCQ) are both 4-aminoquinoline agents that have been used for more than 70 and 50 years, 
respectively, to prevent or to treat malarial infections and later also for treating discoid and systemic lupus erythematosus and rheumatoid 
arthritis. Although HCQ and CQ differ only by one hydroxyl group, the addition of this hydroxyl group results in an important decrease in 
toxicity, while the efficacy remains constant, at least for malaria [1]. Both drugs are available as generic products and mentioned on the 
WHO list of essential medicines. Frequently used trade names of CQ include Avloclor, Nivaquine or Aralen, and the most frequently used 
trade name for HCQ is Plaquenil. 
The mechanisms of action of CQ and HCQ against the malarial Plasmodium parasite and against the auto-immune disorders for which 
they are approved are well known [2–6]. 
Dosage
The dosage of CQ depends on the indication [3, 4]. It should be noted that CQ is often marketed as chloroquine phosphate (CQ-phosphate) 
in tablets of 250 mg, which corresponds to about 150 mg of CQ. All doses mentioned below are doses of CQ-phosphate. High doses (1 g of 
CQ-phosphate per day) are administered in acute phases of malaria or amoebic hepatitis, but only for one or two days. The usual dose for 
long-term use (rheumatoid arthritis and lupus) is 250 mg of CQ-phosphate per day. For HCQ, doses for long-term use range between 200 
and 400 mg per day. Long-term administration of CQ and HCQ in children is not recommended, but doses for long-term treatment between 
2 and 5 mg/kg for HCQ have been reported [7].
Toxicity
Short-term administration of CQ or HCQ rarely causes severe side effects. Longer exposure has been associated with some serious 
though uncommon adverse events [3], including cardiomyopathy [8], irreversible retinal toxicity [9, 10], bone marrow suppression [11] and 
hypoglycaemia [12]. The risk of retinopathy is increased with large cumulative doses of HCQ (>1000 g). However, daily doses up to 400 
mg of HCQ or 250 mg CQ for several years are considered to carry an acceptable risk for CQ-induced retinopathies, with the exception of 
individuals of short stature [13]. It is advised that patients receiving chronic CQ or HCQ therapy be monitored through regular ophthalmic 
examinations (3–6 month intervals), full blood counts and blood glucose level checks. CQ has been associated with some cases of diffuse 
parenchymal lung disease and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome [3]. In case of long-term HCQ 
exposure, skeletal muscle function and tendon reflexes should be monitored for weakness. 
For both CQ and HCQ, specific caution is advised in patients suffering from impaired hepatic function (especially when associated with 
cirrhosis), porphyria, renal disease, epilepsy, psoriasis, glucose-6-phosphate dehydrogenase deficiency and known hypersensitivity to 
4-aminoquinoline compounds [3]. 
Bioavailability
CQ and HCQ are amphiphilic weak bases with the ability to cross cell membranes easily, which is important for their mechanism of action in 
malaria treatment and prophylaxis. CQ and HCQ are partially protonated at the physiologic pH (7.4), but they can be trapped in lysosomes 
(pH 4–5) because of bi-protonation [14]. CQ has pKa values of 8.4 and 10.2, while HCQ has pKa values of 8.3 and 9.7 [14, 15]. 
Both CQ and HCQ have a high bioavailability, 89% and 74% respectively, and a large distribution volume after oral administration. Roughly, 
50%–70% of CQ is protein-bound in the plasma [3]. The terminal elimination half-life of CQ is 1–2 months and for HCQ approximately 50 
days in blood (32 days in plasma). Both drugs are partially metabolised by hepatic dealkylation, but they differ in the number of the metabo-
lites produced. The active metabolites of CQ are monodesethylchloroquine and bisdesethylchloroquine, while HCQ has one extra active 
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metabolite, namely desethylhydroxychloroquine. Moreover, CQ and HCQ are slowly excreted and may still be detected in urine several 
months after administration [3, 4, 9].
Pre-clinical evidence in cancer—in vivo
CQ and HCQ have been extensively studied both in vitro and in vivo in various cancer types. This paper focuses on the results from in vivo 
research, since this is most relevant to clinical practice. Both drugs can be administered as monotherapy or as adjuvant agents to increase 
the efficacy and to limit drug resistance of standard anti-cancer therapy.
Monotherapy
Table 1 lists the main characteristics [animal models, tumour types, animal (H)CQ doses and human equivalent doses (HED)] of the in vivo 
studies performed with CQ or HCQ alone.
Table 1. In vivo studies investigating the efficacy of CQ and HCQ monotherapy.
Reference Animal model Tumour type Animal (H)CQ dose HED[149]
Jutten et al [16] NMRI-nu (nu/nu) female mice Xenografts of U373-EGFRwt 
and U373 control cells
CQ: 60 mg/kg/day for seven 
consecutive days (IP)
292 mg/day
Kim et al [17] NMRI nude mice Xenografts of U87MG cells CQ: Intracranial administration 
of 5µl with a concentration of 
30 mM/day for 17 days
/
Song et al [18] Male athymic BALB/c nu/nu mice Xenografts of CD133+ and 
CD133- cells isolated from Huh 
7 cells 
CQ: 60 mg/kg, twice weekly 
(IP) 
292 mg twice 
weekly
Hu et al [19] Nude mice Xenograft of HepG2-GFP  
human liver
cancer cells
CQ: 80 mg/kg twice daily, on 
a 3-day-on/2-day-off schedule 
for 25 days (SC)
398 mg twice 
daily (3 day-on/2 
day-off)
Lakhter et al [20] NOD-SCID mice Xenografts of SKMel23 cells CQ: 25 mg/kg, twice weekly for 
3 weeks (IP)
122 mg twice 
weekly
Zheng et al [21] Female BALB/c mice Transplantation of CT26 cells CQ: 50 or 25 mg/kg/day for 28 
days (IP)
243 or 122 mg/
day
Jiang et al [22] Female BALB/c mice Transplantation of 4T1 mouse 
cells
CQ: 50 or 25 mg/kg/day for 28 
days (IP)
243 or 122 mg/
day
Loehberg et al [23] Wistar-Furth virgin female rats NMU-induced mammary ad-
enocarcinoma (IP, 50 mg/kg)
CQ: 3.5 mg/kg/week for 3 
weeks (IP)
34 mg/week
Loehberg et al [23] BALB/c mice Transplantation of mammary 
ducts from 7- to 8-week-old 
p53-null BALB/c mice 
CQ: 3.5 mg/kg/week for 8 
weeks (IP)
17 mg/week
Maclean et al [24] ATM-null, p53-null mice (C57BL/6J) 
or Eμ-Myc transgenic mice 
(C57BL/6J) 
Lymphoma CQ: 3.5 mg/kg, every 5 days 
(combined oral/IP or IP alone) 
17 mg every 
5 days
Sun et al [25] Male Sprague Dawley rats DEN-induced hepatocarcinoma CQ: 50 mg/kg, every 3 days 
during week 0 to 9 or during 
week 10 to 17 (IP)
486 mg every 
3 days
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Table 1. continued.
Maes et al [26] Immunocompetent syngeneic (C57/
Bl6) or immunodeficient(nu/nu) mice
Xenografts of A375m and 
transplantation of B16-F10 
mouse cells 
CQ: 50 or 100 mg/kg/day (IP) 243 or 486 mg/ 
day
Maycotte et al [28] Female Nude nu/nu mice Xenografts of MCF7 and MD-
AMB231 cells
CQ: 60 mg/kg/day (IP) 292 mg/day
Yang et al [27] NCr nude mice (Taconic) Xenografts of 8988T, H460 
cells, and panc1 cells and 
an orthotopic PDAC model 
with 8988T cells grown in the 
pancreata
CQ: 60 mg/kg/day (IP) 292 mg/day
Hiraki et al [29] Bashford cancer, Ehrlich ascites and solid cancer, MH134 tumour 
maintained in inbred strains Strong A, C3H, RIll, and RF mice, Yoshida 
ascites and solid tumours carried in Wistar and random-bred rats, and 
Brown-Pearce carcinoma transplanted in albino male rabbits
CQ: 6 - 15 mg/kg/day
(IP, IV, SC, oral) 
58 – 292 mg/day
Pellegrini et al [30] Female NMRI nu/nu mice Xenografts of HCT116 and 
HT29 cells
CQ: 20 mg/kg, every 2 days for 
16 days (IP)
97 mg every 2 
days
Dutta et al [32] Female inbred F344 rats Transplantation of R3230AC 
mammary adenocarcinoma
CQ: 45 mg/kg, 
5 days a week for 25 days (IP)
438 mg 5 days a 
week
Yamaguchi et al [33] Adult female C3H/HeN mice and 
adult male dd-mice
Transplantation of spontane-
ous C3H mammary carcinoma, 
Bashford carcinoma 63 and 
Ehrlich ascites tumours
CQ: 0.2 mg/2 days for 12 days 
(IP)
/
Chi et al [34] Transgenic flies (Drosophila) RasV12 tumours CQ- containing medium (final 
concentration: 1 mg/ml)
/
Rosenfeldt et al [35] KrasG12D/-p53-/- and KrasG12D/-
p53+/+ mice
Pancreatic ductal adenocarci-
noma
HCQ: 60 mg/kg/day (IP) 292 mg/day
Abbreviations: CQ (chloroquine), HCQ (hydroxychloroquine), EGFR (epidermal growth factor receptor), IP (intraperitoneal), NOD SCID mice (non-obese 
diabetic, severe combined immunodeficiency mice), NMU (N-methyl-N-nitrosourea), ATM (ataxia telangiectasia mutated), DEN (diethylnitrosamine), IV 
(intravenous), SC (subcutaneous), HED (Human Equivalent Dose).
Starting with in vivo studies that observed beneficial effects of CQ administration in cancer, Jutten et al noted a delayed tumour growth in 
mice bearing epidermal growth factor receptor (EGFR)-overexpressing glioblastoma xenografts in response to CQ administration. In addi-
tion, the time to reach four times the initial tumour volume was significantly longer in the CQ-treated group [16]. Kim et al confirmed this 
observation in another glioblastoma xenograft mouse study, where CQ was injected intracranially. They observed that the number of mitotic 
cells was significantly reduced and the number of apoptotic cells was increased after CQ administration [17]. In addition, a significant reduc-
tion of tumour volume and tumour incidence was shown by Song et al [18] in mice bearing liver cancer stem cells and Hu et al [19] observed 
significant tumour growth and weight reduction in an orthotopic xenograft model of liver cancer after CQ administration. Lakhter et al [20] 
demonstrated that CQ significantly reduced both tumour volume and tumour mass in a human melanoma xenograft model. Zheng et al [21] 
showed reduced tumour progression and prolonged survival time (not significant) in colon cancer-bearing mice when administering either 
25 or 50 mg/kg of CQ.
Doses of 25 and 50 mg/kg of CQ both significantly increased survival time and reduced primary tumour volume in mice implanted with 
a highly metastasizing breast cancer cell line, as shown by Jiang et al. Interestingly, the number and diameter of lung metastases was 
reduced as well, and CQ enhanced tumour cell apoptosis in the high dose group [22]. 
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The incidence of mammary tumours and their growth rate was significantly lower and tumour onset was delayed in CQ-pre-treated rats after 
being subjected to mammary adenocarcinoma induction using N-methyl-N-nitrosourea (NMU), as shown by Loehberg et al. In wild-type 
BALB/c mice transplanted with mammary ducts of BALB/c p53-null mice, CQ pre-treatment did not affect tumour incidence [23]. Maclean 
et al confirmed that CQ could not prevent spontaneous tumour formation in p53-deficient mice. In contrast, intermittent CQ administration 
significantly reduced the tumour development and doubled the overall survival (OS) of Eμ-Myc mice [24]. 
Furthermore, Sun et al showed that CQ administration is effective in reducing tumour growth in rats with established hepatocarcinoma. In 
contrast, CQ promoted tumour development in the earlier so-called dysplastic stage, clearly illustrating the dual role of autophagy in tumour 
formation (see section on mechanisms of action) [25]. Finally, Maes et al [26] reported that either a dose of 50 mg/kg or a dose of 100 mg/
kg of CQ can reduce tumour growth and cell proliferation, dependent on the cell type. Of note, this study showed that CQ not only inhibits 
autophagy but also affects the tumour microenvironment and tumour vasculature. The exact working mechanisms will be clarified in the 
section on mechanisms of action.
Some studies noted that the efficacy of CQ application in anti-cancer therapy depends on the tumour type that is being treated and sug-
gested that the autophagy dependency of tumour cells might play a role [27, 28]. For example, tumour growth was significantly reduced 
in an MDAMB231 xenograft mouse model, but not in an MCF-7 xenograft mouse model, while both models showed signs of autophagy 
inhibition after CQ treatment [28]. A similar observation can be made when comparing CQ efficacy in pancreatic cancer mouse models 
and a lung cancer mouse model: CQ significantly slowed down tumour growth and increased survival in the first, but not in the latter [27]. 
Another study by Hiraki et al [29] investigated the effects of CQ in various in vivo cancer models and demonstrated that CQ is more effective 
in connective tissue-rich Bashford and Brown–Pearce tumours than in Ehrlich, Yoshida and MH134 tumours. 
A lack of efficacy in certain tumour models could potentially be explained by a study performed by Pellegrini et al exploring the effects of 
CQ under acidic conditions, which mimics the tumour environment. CQ bi-protonation under those conditions could impede cytotoxicity, 
because the cellular uptake of CQ is reduced. This observation highlights a possible limitation of CQ in anti-cancer therapy. However, the 
sensitivity of tumour cells might be restored using tumour pH-modulating agents [30]. Ironically, hypoxic cells that can increase acidification 
of the extracellular space through anaerobe glycolysis are often more autophagy-dependent and, therefore, more sensitive to CQ treat-
ment, as shown by in vitro studies [31].
A limited amount of studies reported potential detrimental effects of CQ and HCQ in in vivo cancer models. First, CQ pre-treatment of rats 
one week before a subcutaneous injection with mammary adenocarcinoma and follow-up treatment for 18 days following this event signifi-
cantly enhanced tumour weight and volume in these rats [32]. Second, in a 1966 paper, very low CQ doses (0.2 mg/2 days) led to a more 
infiltrative morphological pattern of the advancing margin of subcutaneously transplanted mammary carcinoma in mice [33]. Third, malig-
nant tumour growth and metastasis of Ras(V12) cells is observed in transgenic drosophila models after CQ administration [34]. Importantly, 
HCQ promoted tumour growth in Ras-driven pancreatic tumours developing without p53(KrasG12D/+p53–/–) [35]. Collectively, these results on 
a possible detrimental effect of (H)CQ emphasise the importance of the specific tumour setting and tumour characteristics when targeting 
autophagy (see section on mechanisms of action) [35, 36].
Combination therapy
Table 2 summarises the information from articles that studied the effect of CQ (n = 46) or HCQ (n = 5) in vivo in combination with other 
therapies. A more interesting and still under-explored treatment approach for a complex disease such as cancer is to combine various 
anti-cancer agents acting at different levels in the tumour cells and microenvironment [37]. Interestingly, CQ and HCQ have already 
been tested in combination with over 40 other drugs in preclinical cancer research. Both CQ and HCQ can effectively increase the 
efficacy of various anti-cancer drugs, which is further explained in the section on mechanisms of action. Therapies used in combination 
with CQ or HCQ include chemotherapeutic drugs, tyrosine kinase inhibitors, various monoclonal antibodies, hormone therapies and 
radiotherapy (Table 2).
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Table 2. Overview of in vivo research combining known anti-cancer agents with either CQ or HCQ.
Reference (H)CQ Intervention Animal model Tumour type Therapeutic effect of combination 
therapy
Golden et al [150] CQ Temozolomide (TMZ) 4- to 6-week-old male 
athymic nu/nu mice
U87MG glioma cells Higher levels of the proapoptotic protein 
C/EBP homologous protein/growth ar-
rest- and DNA damage-inducible gene 
153 (CHOP/GADD-153)
Zanotto-Filho
et al [151]
CQ TMZ
(+curcumin)
8-week-old male wistar 
rats
C6 brain cells Autophagy inhibition and significantly 
reduced tumour growth 
Gaudin et al [152] CQ Cyclophosphamide 
(Cytoxan)
Golden Syrian hamster Melanoma and plas-
macytoma
Sensitisation to cyclophosphamide
Lefort et al [153] CQ Cyclophosphamide
(+Adriamycin)
6-week-old female 
Swiss nude mice
MDA-MB-231 human 
breast cancer cells 
Significant tumour growth inhibition and 
reduction of lung metastases
Amaravadi
et al [129]
CQ Cyclophosphamide 8-to-10-week-old 
C57BL/6 ×129F1 mice
Myc/p53ERTAM lym-
phomas
Tumour growth inhibition and significant 
delay of tumour recurrence
Yu et al [154] CQ Cisplatin 4-to-6-week-old female 
BALB/c nu/nu mice 
EC109/CDDP human 
oesophageal cells
Significantly lower tumour growth rate 
Zhang et al [155] CQ Cisplatin 8-week-old female 
BALB/c mice
SGC7901 human 
gastric cancer cells 
Significantly reduced tumour volume and 
weight
Zhao et al [156] CQ Cisplatin 5-to-6-week-old 
BALB/c nude mice
FaDu human hypopha-
ryngeal cells
Prolonged survival 
Ding et al [157] CQ Oxaliplatin 4-week-old male athy-
mic BALB/c nude mice
Huh7 hepatocarci-
noma cells 
Significantly reduced tumour volume
Selvakumaran
et al [158]
CQ Oxaliplatin
(+bevacizumab)
8-to-10-week-old 
female C.B.17 SCID 
mice
HT29 human colon 
carcinoma cells
Significant tumour growth delay
Liang et al [107] CQ Carboplatin immunodeficient 
SCID-Beige mice
SUM159 cells breast 
cancer cells (ortho-
topic)
Significantly reduced tumour growth, 
decreased mitochondrial metabolic activ-
ity, decreased cell viability and increased 
levels of LC3b-II and p62 
Balic et al [83] CQ Gemcitabine Immuno-compromised 
mice
patient- derived PDAC 
tumour tissues 
Effective tumour elimination and 
improved overall survival
Shoemaker 
et al [159]
CQ 5-FU Young adult female 
C3H mice
C3HBA mammary 
carcinoma 
Significantly reduced tumour size
Guo et al [160] CQ 5-FU 5-week-old male 
athymic BALB/c nu/
nu mice
SMMC-7721 hepato-
carcinoma cells
Significantly reduced tumour volume and 
weight and significantly higher levels of 
apoptosis
Sasaki et al [161] CQ 5-FU 6-week-old female 
BALB/c mice
Colon26 colon cancer 
cells
Significantly increased inhibition of 
tumour growth and increased number of 
apoptotic cells and proapoptotic protein 
expression levels
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Table 2. continued.
Shoemaker et al 
[162]
CQ 5-FU 
(+ 6-propyl-
thiouracil)
Adult female C3H/He 
mice
C3HBA breast cancer 
cells
Significant tumour reduction
Xiong et al [163] CQ Daunorubicin Female DBA/2 mice 
on a folate-deficient 
diet
L1210JF leukaemia 
cells
No effect
Arnold et al [164] CQ Etoposide Female CBA/Ca mice TLX5 murine ascitic 
tumour cells
Significant improvement in increased life 
span
Cook et al [165] HCQ Tamoxifen and
faslodex 
5-week-old, intact, 
athymic nude mice
Tamoxifen-resistant 
MCF7-RR and faslodex-
resistant /Tamoxifen 
cross-resistant LCC9 
ER+ breast cancer cells
Significantly reduced tumour size and 
tumour wet weight with HCQ and  
tamoxifen, no effect with faslodex and 
HCQ
Loehberg
et al [72]
CQ Everolimus 4-to-6-week-old,  
female NMRI nu/nu 
mice
MCF7 breast cancer 
cells
Significant tumour suppression
Seront et al [166] CQ Rapamycin 8-week–old female 
NMRI nude mice
MDA-MB-231 and 
MCF-7 breast cancer 
cells
Tumour growth reduction in mice 
implanted with large, hypoxic mammary 
tumours (not in smaller tumours)
Bray et al [167] CQ Temsirolimus nude mice RCC4 renal carcinoma 
cells
Significantly reduced tumour growth
Kaneko et al [168] CQ Temsirolimus 4-to-6-week-old 
BALB/c nu/nu and 
BALB/c mice 
CaR-1, HT-29, colon26 
colon cancer cells
Significantly reduced tumour growth
Xie et al [169] HCQ Temsirolimus 6-week-old male nude 
NCr Nu-M mice 
UACC903 melanoma 
cells 
Significantly tumour suppression and 
slower tumour growth
Rao et al [170] CQ Panobinostat NOD/SCID mice MB-231-luciferase 
mammary cells
Slight additional decrease in tumour 
growth as compared to CQ or Panobino-
stat monotherapy, but significant increase 
in survival time
Carew et al [171] CQ Vorinostat Female nude BALB/c 
mice 
HCT8 colon cancer 
cells
Significantly enhanced tumour reduction
Ding et al [172] CQ Bortezomib 6-to-8-week-old female 
BALB/c mice
HCT116 colon cancer 
cells
Significant inhibition of tumour growth 
and higher levels of apoptosis
Hui et al [173] CQ Bortezomib nude mice MHCC-97H and Huh-7 
hepatocarcinoma 
tissues 
Significantly reduced tumour growth and 
increased apoptosis
Tang et al [174] CQ Gefitinib 6-week-old male 
BALB/c nude mice
PC-9/wt and PC-9/
gefB4 lung cancer 
cells 
Significantly reduced tumour growth
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Table 2. continued.
Dragowska
et al [175]
HCQ Gefitinib female Rag2M 
immune-compromised 
mice
JIMT-1 breast cancer 
cells 
58% tumour reduction
Bokobza
et al [176]
CQ Gefitinib
(+ Akt inhibitor)
BALB/c female nude 
mice
HCC-827 lung cancer 
cells 
Significantly inhibited tumour growth 
compared to the control, addition of 
Akt inhibitor or chloroquine to gefitinib 
increased anti-tumour effects, but was 
not found to be significant.
Zou et al [177] HCQ Erlotinib 5-to-6-week-old athy-
mic nude mice
H358 or H460 human 
NSCLC cells
Significant sensitisation to erlotinib 
therapy
Bellodi et al [178] CQ Imatinib Sub-lethally irradiated 
C3H/HeJ mice
MigRI GFP-LC3b–
transduced 32D-
p210BCR/ABL cells
Significant sensitisation to imatinib 
therapy
Abdel-Aziz 
et al [179]
CQ Sunitinib Female Swiss albino 
mice
Ehrlich ascites carci-
noma cells
Significantly reduced tumour growth and 
weight 
Shimizu 
et al [180]
CQ Sorafenib BALB/c nude mice Huh7 hepato-carcino-
ma cells
Significantly suppressed tumour growth
Shi et al [181] CQ Sorafenib Male athymic BALB/c 
nude mice
MHCC97-L hepatocel-
lular cells
Significantly reduced tumour growth and 
increased apoptosis
Ji et al [182] CQ Crizotinib 6- to 7-week-old fe-
male CD-1 nude mice
crizotinib-resistant 
H3122CR-1 lung can-
cer cells
Sensitisation of drug resistant lung can-
cer cells to crizotinib
You et al [183] HCQ Crizotinib 5-to-6-week-old female 
athymic BALB/c nude 
mice
SPC-A1 human lung 
cancer cells
Significantly reduced tumour growth and 
increased apoptosis
Mitou et al [184] CQ Crizotinib 6-week-old female 
NOD-SCID mice
Karpas-299 lymphoma 
cells
Significantly reduced tumour growth and 
increased apoptosis
Shen et al [185] CQ Vandetanib 6-to-8-week-old female 
BALB/c nude mice
U251 glioblastoma 
cells 
Significantly reduced tumour growth and 
increased apoptosis
Hu et al [186] CQ Bevacizumab 6-to-8-week-old female 
BALB/c nu/nu mice
1) GBM39 primary 
glioma cells
2) Subcutaneous 
U87MG glioma cells
3) G55 glioma cells
4) patient-specimen 
derived SF8244 cells
Significantly suppressed GBM39, 
U87MG, G55, and patient specimen-
derived SF8244 tumour growth
Selvakumaran
et al [158]
CQ Bevacizumab
(+ oxaliplatin)
8-to-10-week-old 
female C.B.17 SCID 
mice
HT29 human colon 
carcinoma cells
Significantly delayed tumour growth
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Table 2. continued.
Cufi et al [187] CQ Trastuzumab 4-to-5-week-old female 
athymic nude mice
JIMT-1 breast cancer 
cells 
Significantly reduced tumour growth and 
increased Bax/Bcl-2 ratio
Gaudin et al [152] CQ Radiotherapy Golden Syrian hamster Melanoma and  
plasma cytoma
Increased sensitivity of melanoma and 
plasma cytoma tumour cells to X-rays
Ratikan et al [188] CQ Radiotherapy 6-week-old female  
H-2 3H/Sed//Kam and 
H-2 Rag2-/-, gamma  
c -/-mice
MCaK breast cancer 
cells
Significantly higher cure rate,  
delayed tumour growth and enhanced 
immunogenicity
Wei et al [189] CQ PDT NOD/SCID mice PROM1/CD133+ 
colorectal cancer
stem cells
Restoration of sensitivity to PDT
Liang et al [190] CQ HDIL-2 8-to-10-week-old 
female C57BL/6
(B6, H-2b) mice
luciferase-labeled 
mouse MC38 colorec-
tal cancer cells 
Significantly reduced tumour growth and 
prolonged survival time
Thomas et al [191] CQ Nelfinavir
Celecoxib
Athymic mice MDA-MB-468 and 
MCF-7 breast cancer 
cells 
Triple-drug treatment displayed obvious 
anti-cancer
effects in both TNBC (MDA-MB-468) and 
non-TNBC (MCF-7) xenograft (=proof of 
principle study, more extensive in vivo 
experiments needed)
Harhaji-Trajkovic et 
al [192]
CQ Caloric restriction 5-to-6-week-old female 
C57BL/6 mice
B16 melanoma cells Combination of CQ and caloric restric-
tion almost completely abolished B16 
melanoma growth
Thomas et al [193] CQ Hyperthermia male white Ajax mice C-1300 murine neuro-
blastoma
! Increased tumour growth and metas-
tasis
Gao et al [194] CQ TACE Adult New Zealand 
White rabbits
VX2 liver tumours Significantly reduced tumour volume and 
growth rate
Abbreviations: CQ (chloroquine), HCQ (hydroxychloroquine), SCID (severe combined immunodeficiency mice), PDAC (pancreatic ductal adenocarcino-
ma), 5-FU (5-fluorouracil) NOD (non-obese diabetic), wt (wild-type), PDT (photodynamic therapy), HDIL-2 (high-dose interleukin-2), TACE (transcatheter 
arterial chemoembolisation)
Human data
Numerous clinical trials in which either CQ or HCQ is being used to treat patients with a range of cancer types are registered in clinical 
trial databases. In clinical trials, these drugs are most often administered in combination with other anti-cancer agents. More information 
on the registered clinical trials is provided in Tables 3 and 4, for CQ and HCQ, respectively. Few trials have been completed. Therefore, 
limited published data are available on the safety and therapeutic efficacy of these antimalarial drugs in cancer. A schematic overview of 
the published clinical trial data of CQ and HCQ can be found in Tables 5 and 6, respectively. 
In the next section, the clinical effects of CQ and HCQ will be discussed separately because important differences can be observed in 
toxicity and efficacy of both drugs.
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Table 3. Information on clinical trials investigating CQ use in cancer (Source: ClinicalTrials.gov).
ClinicalTrials.gov ID Type of cancer Intervention Study 
Phase
Location Status First  
received
Last verified
NCT00224978 GBM CQ
(+ conventional 
treatment)
Phase 3 Mexico Completed Sept 2005 Nov 2009
NCT01438177 Multiple myeloma CQ,
Velcade,  
Cyclophosphamide
Phase 2 US Completed, 
has results
Sept 2011 June 2016
NCT01727531 Brain metastasis CQ, 
Radiation therapy 
Not provided US Completed Nov 2012 Apr 2015
NCT01777477 Pancreatic cancer CQ, 
Gemcitabine 
Phase 1 Switzerland Completed Jan 2013 Sept 2015
NCT01894633 Brain metastasis CQ,  
Radiotherapy 
Phase 2 Mexico Terminated June 2013 July 2013
NCT01469455 Local metastatic  
melanoma
CQ,
DT01, 
Radiotherapy
Phase 1 France Completed Oct 2011 June 2016
NCT01023477 Ductal carcinoma in situ CQ 
(Procedure: breast 
biopsy)
Phase 1 - 2 US Ongoing Dec 2009 Sept 2016
NCT00969306 Small cell lung cancer CQ Phase 1 The Netherlands Recruiting Aug 2009 Feb 2016
NCT01446016 Breast cancer CQ,
Taxane, 
Taxotere, 
Abraxane, 
Ixabepilone
Phase 2 US Recruiting Sept 2011 Sept 2016
NCT01575782 Small cell lung cancer CQ,
Radiotherapy
Phase 1 The Netherlands Recruiting Apr 2012 Sept 2016
NCT02071537 Advanced solid tumours CQ, 
Carboplatin,  
Gemcitabine
Phase 1 US Recruiting Feb 2014 Dec 2015
NCT02333890 Breast cancer CQ (and placebo)
(prior to surgery)
Phase 2 Canada Recruiting Jan 2015 Nov 2016
NCT02366884 Neoplasms Anti-Bacterial 
Agents, 
Anti-Fungal Agents, 
Anti-Protozoal 
Agents
Phase 2 Mexico Recruiting Feb 2015 Aug 2015
NCT02496741 Glioma, 
Cholangiocarcinoma, 
Chondrosarcoma
CQ, 
Metformin 
Phase 1 - 2 The Netherlands Recruiting June 2015 Nov 2015
NCT02378532 GBM CQ, 
Radiotherapy, 
Temozolomide
Phase 1 The Netherlands Recruiting Feb 2015 Aug 2016
NCT02432417 Glioblastoma, 
Astrocytoma (Grade IV)
CQ,  
Radiotherapy
Phase 2 Not provided Not yet 
recruiting
Apr 2015 Apr 2016
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Table 3. continued.
NCT03243461 Glioblastoma WHO 
Grade IV, Diffuse Mid-
line Glioma Histone 3 
K27M, WHO Grade IV 
Anaplastic Astrocytoma 
WHO Grade III, Diffuse 
Intrinsic Pontine Glioma, 
Gliomatosis Cerebri
Radiochemotherapy 
with 
Temozolomide, 
Valproic Acid or 
Chloroquine
Phase 3 Germany Not yet 
recruiting
Aug 2017 Oct 2017
Table 4. Information on clinical trials investigating HCQ use in cancer (Source: ClinicalTrials.gov).
ClinicalTrials.
gov ID
Type of cancer Intervention Study Phase Location Status First  
received
Last verified
NCT00765765 Breast cancer HCQ,  
Ixabepilone
Phase 1 - 2 US Terminated,  
has results
Oct 2008 Nov 2013
NCT00786682 Prostate cancer HCQ, 
Docetaxel
Phase 2 US Terminated,  
has results
Nov 2008 Sept 2013
NCT00728845 Lung cancer HCQ,
Bevacizumab,  
Carboplatin, 
Paclitaxel 
Phase 1 - 2 US Terminated,  
has results
Aug 2008 Sept 2013
NCT01026844 Non-small cell lung  
cancer
HCQ, 
Erlotinib
Phase 1 US Terminated,  
has results
Dec 2009 June 2013
NCT01842594 Soft tissue sarcoma HCQ, 
Sirolimus
Phase 2 Taiwan Terminated, 
has results
Dec 2012 Oct 2015
NCT01144169 Renal cell carcinoma HCQ 
(prior to surgery)
Phase 1 US Terminated June 2010 Oct 2016
NCT01417403 Bone metastases 
unspecified adult solid 
tumour
HCQ,  
Radiation therapy 
Phase 1 US Terminated Aug 2011 Feb 2015
NCT00771056 B-cell chronic lympho-
cytic leukaemia
HCQ Phase 2 US Terminated Oct 2008 Aug 2016
NCT00714181 Unspecified adult  
solid tumour
HCQ,  
Temozolomide
Phase 1 US Completed July 2008 Feb 2016
NCT01396200 Multiple myeloma HCQ, 
Rapamycin, 
Cyclophosphamide, 
Dexamethasone
Phase 0 US Completed July 2011 Feb 2013 
NCT01634893 Refractory or relapsed 
solid tumours
HCQ, 
Sorafenib
Phase 1 US Completed July 2012 Mar 2016
NCT01828476 Prostate cancer HCQ, 
Abiraterone, 
ABT-263 
Phase 2 US Completed Mar 2013 Mar 2016
NCT01006369 Colorectal cancer HCQ,
Bevacizumab,  
FOLFOX6,  
XELOX regimen
(capecitabine,  
oxaliplatin) 
Phase 2 US Suspended Oct 2009 Dec 2014
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Table 4. continued.
NCT00726596 Prostate cancer HCQ Phase 2 US Ongoing July 2008 Dec 2015
NCT00813423 Adult solid neoplasm HCQ,  
Sunitinib malate
Phase 1 US Ongoing Dec 2008 Nov 2016
NCT00909831 Unspecified adult  
solid tumour
HCQ, 
Temsirolimus
Phase 1 US Ongoing May 2009 Feb 2016
NCT00962845 Melanoma HCQ (prior to 
surgery)
Phase 0 US Ongoing Aug 2009 July 2016
NCT00977470 Non-small cell lung  
cancer
HCQ,
Erlotinib
Phase 2 US Ongoing Sept 2009 Sept 2016
NCT01128296 Pancreatic cancer HCQ,  
Gemcitabine (prior 
to surgery)
Phase 1 - 2 US Ongoing May 2010 Jan 2015
NCT01273805 Pancreatic cancer HCQ Phase 2 US Ongoing Jan 2011 Jan 2016
NCT01480154 Advanced solid  
tumours, melanoma, 
prostate or kidney cancer
HCQ,
Akt Inhibitor 
MK2206
Phase 1 US Ongoing Nov 2011 Feb 2016
NCT01689987 Relapsed or refractory 
multiple myeloma
HCQ,
Cyclophosphamide,  
Dexamethasone,  
Sirolimus
Phase 1 US Ongoing Sept 2012 Aug 2016
NCT01897116 Melanoma HCQ, 
Vemurafenib
Phase 1 US Ongoing June 2013 July 2016
NCT02421575 Prostate cancer HCQ (before  
prostatectomy or 
local therapy)
Phase 0 US Ongoing Dec 2014 July 2016
NCT01494155 Pancreatic cancer HCQ,
Capecitabine,  
Radiation: Proton or 
Photon
Radiation Therapy 
Phase 2 US Ongoing July 2011 Sept 2016
NCT01602588 Glioblastoma HCQ, 
Short Course  
radiotherapy
Phase 2 UK Ongoing May 2012 Nov 2016
NCT02470468 Stage IV non-small  
cell lung cancer
DCVAC, 
Standard of Care 
Chemotherapy 
(Carboplatin,  
Paclitaxel), 
Immune enhancers 
(Interferon-α and 
HCQ) 
Phase 1 - 2 Czech  
Republic 
and 
Slovakia
Ongoing June 2015 Nov 2016
NCT01023737 Malignant solid tumour HCQ, 
Vorinostat
Phase 1 US Recruiting July 2009 Sept 2016
NCT01206530 Colorectal cancer HCQ,  
Oxaliplatin,  
Leucovorin,  
5-fluorouracil,  
Bevacizumab
Phase 1 - 2 US Recruiting Sept 2010 Sept 2016
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Table 4. continued.
NCT01266057 Advanced cancers HCQ,  
Sirolimus,  
Vorinostat
Phase 1 US Recruiting Dec 2010 Nov 2016
NCT01510119 Renal cell carcinoma HCQ,  
RAD001
Phase 1 - 2 US Recruiting Jan 2012 Dec 2015
NCT01506973 Advanced and  
metastatic adenocarci-
noma
HCQ, 
Gemcitabine/ab-
raxane
Phase 1 - 2 US Recruiting Jan 2012 Sept 2016
NCT01550367 Metastatic renal cell  
carcinoma
HCQ,  
IL-2 
Phase 1 - 2 US Recruiting Feb 2012 May 2015
NCT01649947 Non-small cell lung  
cancer 
HCQ,
Paclitaxel, 
Carboplatin,  
Bevacizumab
Phase 2 US Recruiting July 2012 July 2016
NCT01978184 Pancreatic cancer HCQ,
Gemcitabine,  
Abraxane
Phase 2 US Recruiting Oct 2013 Dec 2015
NCT02013778 Hepatocellular carcinoma HCQ,  
TACE
Phase 1 - 2 US Recruiting Dec 2013 Sept 2016
NCT02232243 Solid tumour HCQ (prior to 
surgery)
Phase 1 US Recruiting Sept 2014 Oct 2016
NCT02257424 Advanced BRAF  
mutant melanoma
HCQ,
Dabrafenib, 
Trametinib
Phase 1 - 2 US Recruiting Oct 2014 June 2016
NCT02316340 Colorectal cancer HCQ, 
Vorinostat,  
Regorafenib
Phase 2 US Recruiting Dec 2014 Sept 2016
NCT02414776 Oestrogen receptor  
positive breast cancer
HCQ, 
Hormonal therapy
Phase 1 
(1b/2)
US Recruiting Jan 2015 Apr 2015
NCT02631252 Acute myeloid leukaemia HCQ, 
Mitoxantrone, 
Etoposide
Phase 1 US Not yet  
recruiting
Dec 2015 Dec 2015
NCT02722369 Small cell lung cancer HCQ,
Gemcitabine, 
Carboplatin, 
Etoposide
Phase 2 Not  
provided
Not yet  
recruiting
Mar 2016 Nov 2016
NCT00486603 Brain and central  
nervous system tumours
HCQ,  
Temozolomide,  
Radiation
Phase 1 - 2 US Unknown June 2007 May 2012
NCT00568880 Multiple myeloma and 
plasma cell neoplasms
HCQ,
Bortezomib
Phase 3 US Unknown Dec 2007 July 2009
NCT00809237 Non-small cell lung  
cancer
HCQ,
Gefitinib
Phase 1 - 2 Singapore Unknown Dec 2008 Dec 2013
NCT01227135 Chronic myeloid  
leukaemia
HCQ,  
Imatinibmesylate
Phase 2 UK Unknown Oct 2010 Nov 2011
NCT01292408 Breast cancer HCQ Phase 2 The Netherlands Unknown Dec 2010 Jan 2012
Abbreviations: FOLFOX6 (folinic acid – 5- fluorouracil – oxaliplatin), XELOX (capecitabine – oxaliplatin), IL-2 (interleukin-2), TACE (trans catheter arterial 
chemoembolisation), DCVAC (dendritic-cell based immunotherapy)
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Table 5. Publications reporting clinical trial results on CQ use in cancer.
Article Tumour type Phase Intervention CQ dose # patients
Therapeutic 
response
Briceño et al [38]
Glioblastoma 
multiforme Unknown
CQ + conventional 
cancer treatment 150 mg/day 18 (9 CQ + 9 control) Positive
Sotelo et al [39]
Glioblastoma 
multiforme Phase 3
CQ + conventional 
cancer treatment 150 mg/day 30 (15 CQ + 15 control) Partial 
Briceño et al [41]
Glioblastoma 
multiforme
Retrospec-
tive  
study 
based on 
patient 
data
CQ + conventional 
cancer treatment 150 mg/day
123 (41 CQ + 82 
control) Positive
Rojas-Puentes  
et al [43] Brain metastases Phase 2 CQ + radiotherapy 150 mg/day 73 (39 CQ + 34 control) Partial 
Eldredge et al [44] Brain metastases Unknown CQ + radiotherapy 250 mg/day 20 (all CQ, no control) Partial
Montanari et al [49]
Relapsed and refractory 
multiple myeloma
Phase 
1 - 2
CQ + bortezomib + 
cyclophosphamide 500 mg/day 8 (all CQ, no control) Partial
Kyle et al [50] Multiple myeloma Unknown
CQ + prednisone + 
cyclophosphamide +
caffeine 2x 250 mg/day 38 (18 CQ + 20 control) Absent
Table 6. Publications reporting clinical trial results on HCQ use in cancer.
Article Tumour type Phase Intervention HCQ dose # patients
Therapeutic 
response
Rangwala et al [51]
Advanced solid tumours  
and melanoma Phase 1 HCQ + temsirolimus RD: 2x 600 mg/day 39 (all HCQ, no control) Partial
Rangwala et al [52]
Advanced solid tumours  
and melanoma Phase 1 HCQ + temozolomide RD: 2x 600 mg/day 40 (all HCQ, no control) Partial
Mahalingam et al 
[53] Advanced solid tumours Phase 1 HCQ + vorinostat MTD: 600 mg/day 27 (all HCQ, no control) Partial
Chi et al [54] Stage IV solid tumours Pilot
HCQ + sirolimus + 
chemotherapy 400 mg/day 25 (all HCQ, no control) Partial
Rosenfeld et al [55] GBM Phase 1–2
HCQ + radiotherapy 
+ temozolomide MTD: 600 mg/day 92 (all HCQ, no control) Absent
Goldberg et al [57] Advanced NSCLC Phase 1 HCQ + erlotinib RD: 1000 mg/day 27 (all HCQ, no control) Partial
Vogl et al [59]
Relapsed and refractory 
multiple myeloma Phase 1 HCQ + bortezomib RD: 2x 600 mg/day 25 (all HCQ, no control) Partial
Boone et al [60]
Pancreatic adenocarci-
noma Phase 1–2 HCQ + gemcitabine RD: 1200 mg/day 35 (all HCQ, no control) Partial
Wolpin et al [61]
Metastatic pancreatic  
adenocarcinoma Phase 2 HCQ 
400 and 600 mg/
day 20 (all HCQ, no control) Absent
Chi et al [62] Sarcoma Phase 2 HCQ + sirolimus 2x 200 mg/day 10 (all HCQ, no control)
Absent, study 
was closed 
prematurely
Abbreviations: MTD (maximal tolerated dose), RD (recommended dose), NSCLC (non-small cell lung cancer)
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CQ
Glioma and brain metastases
In May 1998, one of the first clinical trials on CQ use in cancer was started, which was an open, prospective, randomised controlled 
study with 18 glioblastoma multiforme (GBM) patients [38]. The test group consisted of nine patients who received 150 mg CQ daily after 
resection of the lesion, in addition to radiotherapy (total dose of 6000 Gy) and four cycles of carmustine-chemotherapy every six weeks 
(200 mg/m2), while the nine patients in the control group received placebo instead of CQ. In the abstract of this study, the authors reported 
that adjuvant CQ administration significantly enhanced patient survival [33 ± 5 months for CQ-treated patients and 11 ± 2 months for con-
trols (p < 0.0002)]. Due to some inconsistencies in the report, the calculation of the mean survival in the CQ-treated group is unclear, but the 
Kaplan Meier analysis remains significant. A higher seizure frequency was observed in the CQ-treated group and could not be explained. 
However, standard antiepileptic treatment was reported to easily suppress these seizures. The same group of researchers started a similar 
randomised, double blind, placebo-controlled study in October 2000 [39]. In this second study, 15 GBM patients received 150 mg CQ each 
day for 12 months after surgery in combination with their conventional anti-cancer therapy, four cycles of carmustine-chemotherapy every 
five weeks (200 mg/m2) and a total radiation dose of 60 Gy; the other 15 patients received adjuvant placebo treatment. A median survival 
time of 24 months was observed in the CQ-treated group, as compared with 11 months in the control group. In addition, the hazard ratio for 
death was approximately half as large in the patients receiving CQ though this was not statistically significant (hazard ratio: 0.52, [95% CI 
0.21–1.26, p = 0.139]). No important adverse effects were noted in this trial. The small sample size is an important limitation in both stud-
ies, and larger clinical trials are needed to confirm the efficacy of CQ in GBM therapy [39, 40]. In a retrospective study, the same research 
group looked at data collected over five years from 41 GBM patients in Mexico who received adjuvant CQ therapy and did not participate 
in the previously mentioned clinical trials [41]. The mean survival time of these CQ-treated patients was significantly longer compared with 
a control group of 82 glioblastoma patients [25 ± 3.4 months and 11.4 ± 1.3 months after surgery respectively (p = 0.000)].
After the observation of promising outcomes in five recurrent GBM patients treated with 250 mg CQ a day and reirradiation for 20 months 
[42], a phase-2 clinical trial tested the effects of CQ as a radio-sensitising agent in patients with brain metastases [43]. In this trial, 39 
patients were administered whole-brain irradiation (30 Gy in 10 fractions over two weeks) in combination with a daily dose of 150 mg CQ 
for four weeks, while 34 patients received placebo instead of CQ in addition to the same radiation treatment. The overall response rate or 
OS did not improve after CQ administration. However, the progression-free survival of brain metastases rate was increased (CQ-treated 
group: 83.9% [95% CI 69.4–98.4] and control group: 55.1% [95% CI 33.6–77.6] (at one year), relative risk: 0.31 [95% CI 0.1–0.9, p = 
0.046]). The absence of adverse effects and the improved local control of brain metastases indicate that CQ might be a useful addition to 
whole brain irradiation in patients with brain metastases. In a prospective, single-cohort study of 20 patients with brain metastases from 
solid tumours, 250 mg CQ daily was administered for five weeks in combination with whole-brain irradiation [44]. The intracranial response 
rate corresponded to an objective clinical response of 93% after three months of whole-brain irradiation, there was a slight, positive trend 
in OS (median OS of 5.7 months, compared with 4.2 months for patients in class II estimated by the radiation therapy oncology group 
recursive partitioning analysis), and no adverse reactions were detected. Finally, two case reports mentioned unusual skin reactions after 
concomitant use of CQ and radiation, illustrating the radio-sensitising effect of CQ [45, 46].
In a paediatric patient with a recurrent BRAF V600E mutant brainstem ganglioglioma, tumour growth was blocked and vemurafenib sensi-
tivity restored following treatment with 150 mg CQ daily for at least 30 months [47, 48]. The same research group reported in vitro and ex 
vivo data showing that autophagy inhibition was able to improve the response to BRAF inhibition in resistant tumour cells [48]. Next, CQ 
was administered to two patients with acquired resistance to BRAF inhibition. The first patient was treated with standard doses of vemu-
rafenib plus 250 mg daily of CQ during focal radiation of large primary lesions. Vemurafenib was continued and the CQ dose was increased 
to 500 mg daily after completion of radiation. A rapid favourable clinical response to the combination therapy was observed in as little as 
six weeks and was maintained for seven months, at which point the patient had to stop therapy for unrelated medical issues. The second 
patient was treated with 500 mg CQ daily in combination with standard dosing of vemurafenib. Acquired resistance to vemurafenib was 
overcome within four weeks of the addition of CQ and clinical improvement could be observed, which was maintained for two and a half 
months. However, therapy had to be stopped and the family chose to pursue palliative therapy afterwards. 
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Multiple myeloma
Eleven patients with relapsed and refractory multiple myeloma were enrolled and treated with 500 mg CQ daily (on days 1–14 and 22–35) 
in addition to bortezomib and cyclophosphamide (administered orally twice daily) in a phase-2 clinical trial [49]. Of these eleven patients, 
only eight patients were evaluable. CQ was able to partially restore the bortezomib sensitivity: three patients had a partial response, one 
had stable disease and four had progression as best responses.
The adjuvant therapeutic effect of 250 mg CQ twice daily in combination with cyclophosphamide and prednisone was tested for a period 
of ten days in 38 myeloma patients [50]. Twenty patients received cyclophosphamide and prednisone, while the other 18 patients received 
extra treatment with CQ and caffeine, but no additional response was observed in the CQ-treated patient group.
HCQ
Solid cancers
The effect of HCQ and temsirolimus combination therapy was tested in 27 patients with advanced solid cancer during a phase-1 dose-escalating 
study and subsequently in 13 patients with metastatic melanoma at the phase-2 recommended dose [51]. No patient experienced an objec-
tive response but 19 out of the 27 phase-1 patients (73%) and 9 out of 13 melanoma patients (69%) had stable disease. In patients with stable 
disease, HCQ addition was shown to produce metabolic stress in the tumours. Inhibition of autophagy (see section on mechanisms of action), 
measured by counting the number of autophagic vacuoles per cell in tumour tissues and peripheral blood mononuclear cells of patients, was only 
noted in patients receiving at least 1200 mg HCQ daily. This study recommends an adjuvant HCQ dose of 600 mg, twice daily.
Next, the combinatory effect of HCQ and temozolomide was investigated in 40 cancer patients with advanced solid tumours and mela-
noma, and the recommended dose of 600 mg twice daily was confirmed [52]. HCQ was shown to successfully inhibit autophagy, as evi-
denced by the significant accumulation of autophagic vacuoles in peripheral blood mononuclear cells (mean autophagic vacuole counts: 
2.19 at baseline, 2.45 after HCQ treatment, 3.84 after treatment with HCQ plus TMZ [difference between HCQ plus TMZ and baseline: p = 
0.0007, difference between HCQ plus TMZ and HCQ only: p = 0.0034]). 
The safety and preliminary efficacy of HCQ and vorinostat combination treatment was tested during a phase-1 study in 27 patients with 
advanced solid tumours [53]. In this study, the maximum-tolerated HCQ dose was set at 600 mg daily in combination with 400-mg vorino-
stat. A confirmed durable partial response was observed in a renal cell carcinoma patient, and prolonged stable disease was seen in two 
colorectal cancer patients. In contrast to the previous study, autophagy was not significantly affected.
Finally, in a pilot retrospective study, 25 stage-IV cancer patients (various types) who had no clinical response to maximally tolerated che-
motherapy and to first-line metronomic chemotherapy were treated with sirolimus (2 mg/day) and the autophagy inhibitor HCQ (400 mg/
day) in addition to their current metronomic chemotherapy for at least three months. The therapy was reported to be relatively safe, and 
the overall response rate was 40%, with an 84% disease control rate [54]. However, this was a retrospective analysis requiring cautious 
interpretation.
Glioblastoma
The efficacy and safety of HCQ was studied in combination with radiotherapy and temozolomide in 92 GBM patients during a phase-1–2 
study [55]. This study indicated a maximum tolerated dose (MTD) of 600 mg HCQ a day in this therapeutic setting. OS did not seem to 
be affected in comparison with the temozolomide arm of the trial reported by Stupp [56], and autophagy was not found to be consistently 
inhibited in all patients.
Lung cancer
The combination of HCQ with erlotinib can be used safely in daily doses of 150 mg erlotinib and 1000 mg HCQ, as determined by a phase-1 
study in 27 patients with advanced non-small cell lung cancer (NSCLC) [57]. Of the 19 patients who remained in the study, one had a partial 
response and four had stable disease as best response. Subsequent ophthalmic surveillance on seven trial participants who had taken 
HCQ for a duration longer than six months showed that retinal toxicity occurred in two patients after 11 and 17 months of exposure [58]. 
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This highlights the importance of retinal toxicity monitoring (via high-resolution spectral-domain optical coherence tomography, fundus auto 
fluorescence imaging, Humphrey visual field testing and multifocal electroretinography) during clinical trials with HCQ.
Multiple myeloma
During a phase-1 study, the safety of the combination of HCQ and bortezomib was explored in 25 patients with relapsed or refractory 
myeloma [59]. A dose of 600 mg HCQ twice daily was reported to be safe and tolerable in combination with standard doses of bortezomib. 
The increase in the number of autophagic vacuoles was not significantly associated with clinical response or HCQ exposure. Of 22 evalu-
able patients, three (14%) had very good partial responses, three (14%) had minor responses, ten (45%) had stable disease for at least 
one cycle and six (27%) had immediate progression.
Pancreatic cancer
The safety of the combination of pre-operative HCQ (1200 mg daily) and gemcitabine administration was demonstrated in 35 patients with 
pancreatic adenocarcinoma in a phase-1–2 trial [60]. This study reported promising clinical response markers (e.g. CA 19–9 biomarker 
and R0 resection rate). An exploratory analysis showed significantly improved disease-free survival and OS (15.03 versus 6.9 months and 
34.83 versus 10.83 months, respectively) in patients for whom autophagy was sufficiently inhibited (n = 8) (at least 51% increase in the 
autophagy marker LC3B-II in peripheral blood mononuclear cells) compared with other patients (n = 9). 
Next, a phase-2 study investigated the safety and efficacy of HCQ monotherapy with either 400 or 600 mg two times a day in 20 patients 
with previously treated metastatic pancreatic cancer, but no significant differences were observed between groups [61]. In addition, inhibi-
tion of autophagy could not be achieved consistently, as shown by LC3B-II analysis in the lymphocytes of patients, and the two-month 
progression-free survival rate was only 10%. 
Sarcoma
The combination of 1 mg sirolimus and 200 mg HCQ twice daily for two weeks was tested in ten sarcoma patients who had failed first-line 
treatment [62]. This study started from the hypothesis that there is metabolic symbiotic relationship between cancer-associated fibroblasts 
(CAFs) and sarcoma cells (see mechanisms of action). The study showed that this relationship might be altered by treatment with sirolimus 
and HCQ as glycolysis was inhibited within the tumours. Based on FDG PET response criteria, two weeks after treatment initiation, six 
patients showed partial response, three had stable disease and one had progressive disease. However, most patients discontinued treat-
ment before the initially planned eight-week response assessment, for disease progression.
Mechanism of action
Multiple hypotheses have been proposed on how CQ and HCQ exert their anti-cancer activity. Most studies reported the direct action of 
these drugs on cancer cells, but more recent studies have also mentioned important effects of CQ and HCQ on the tumour microenviron-
ment. Based on preclinical studies, it is safe to say that CQ and HCQ have multiple mechanisms of action that might complement each 
other. 
The most relevant and evidence-based mechanisms of action of CQ and HCQ in anti-cancer treatment will be briefly explained in the next 
section. The benefits of combining these antimalarial drugs with existing anti-cancer treatments will also be described. In the final section, 
the variation in sensitivity of cancer patients to CQ and HCQ therapy will be clarified.
Direct anti-tumour effects
The main and most studied anti-cancer effect of CQ and HCQ is the inhibition of autophagy, but other preclinically proven anti-cancer 
activities of the antimalarial agents include influencing the TLR9/nuclear factor kappa B (NF-κB) signalling pathway, the CXCL12/CXCR4 
signalling pathway and the p53 pathway.
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Autophagy inhibition
Autophagy literally means ‘self-eating’. It is a process in which a cell destroys old or defective cellular components, thereby releasing cel-
lular building blocks including nucleotides, amino acids and fatty acids. Those degradation products can later be recycled by the cell to meet 
its metabolic needs. Autophagy is an essential intracellular process to ensure cell survival under stressful conditions (e.g. hypoxia, starva-
tion and organelle damage). Different types of autophagy exist but, here, we will use the term to refer to macroautophagy. Autophagy is a 
complex multi-faceted process [63]. One putative biomarker is the level of LC3B-II, an essential protein during autophagosome formation 
and the level of scaffolding protein p62 [or sequestosome 1 (SQSTM1)] [64, 65]. Autophagy has both pro-tumour and anti-tumour functions, 
which may be both stage and tissue-type specific.
In early carcinogenesis, autophagy has a tumour suppressive role since it has an important quality control function and protects the cell by 
sequestering and eliminating defective cellular components, such as damaged mitochondria, and by maintaining cellular homeostasis [66, 
67]. In addition, several autophagic proteins can directly suppress tumour formation (e.g. Beclin-1, UVRAG and Bif-1) and autophagy has 
been shown to degrade tumour promoting proteins as well (e.g. p62/SQSTM1) [68]. In line, deregulation of autophagy has been repeatedly 
associated with human cancers [67]. 
In contrast, autophagy can promote tumour growth in more advanced stages of cancer [69]. Pro-survival autophagy is induced in response 
to a variety of stressful conditions including but not limited to, starvation, loss of proteostasis, organelle damage and hypoxia. Some 
anti-cancer treatments can also induce pro-survival autophagy. Autophagic properties such as nutrient recycling can support cancer cell 
survival. Moreover, key regulators of cell growth can be degraded and the DNA damage response can be suppressed through increased 
autophagy [66–68]. Therefore, inhibition of autophagy can be an interesting anti-cancer strategy when cancer cells start depending on 
autophagy for survival, a moment called the autophagic switch [64, 70]. 
CQ and HCQ inhibit the autophagic flux at a late stage (Figure 1): the fusion of the autophagosomes with the lysosomes and subsequent 
degradation of the autolysosome. Upon entering the lysosomes, CQ and HQ become protonated, which leads to their entrapment in acidic 
lysosomes and an increase in the lysosomal pH, which inhibits the lysosomal degradative enzymes [71]. Loehberg et al [72] suggested that 
CQ might also modulate autophagy by modifying the PI3K/Akt/mTOR pathway.
In summary, autophagy plays a dual role in cancer and the success of autophagy inhibition, using the late stage inhibitors CQ and HCQ, 
depends on the timing and context. Autophagy is an interesting therapeutic target after the autophagic switch. However, the autophagy 
dependency of the tumour cells and any combinatory therapies can influence the sensitivity to autophagy inhibition, which will be 
discussed later. 
Figure 1. Autophagic process. (1) Elongation of the phagophore and vesicle formation. (2) Fusion of the autophagosome and a lysosome. 
(3) Destruction of the engulfed cellular components by lysosomal hydrolases. CQ and HCQ inhibit autophagy through interference with the 
lysosomal acidification (Step 2). 
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Inhibition of the TLR9/nuclear factor kappa B signalling pathway
TLR9, a member of the Toll-like receptor family, is located in the endosomal compartment. This receptor recognises unmethylated single 
stranded DNA and is necessary for pathogen recognition and innate immune system activation. In cancer, expression and stimulation of 
TLR9 is linked with invasiveness, as shown in in vitro experiments [73–75]. Moreover, the expression levels of TLR9 are higher in hepato-
cellular carcinoma, oesophageal, lung, breast, gastric and prostate cancer cells as compared with adjacent noncancerous cells, and high 
expression is often linked with poor prognosis [73–76]. Because of this observation, it was suggested that TLR9 might be an appropriate 
anti-cancer target [73, 74, 76]. 
The TLR9-mediated activation of the NF-κB signalling pathway and the associated enhanced expression of matrix metalloproteinase-2 
(MMP-2), MMP-7 and cyclo-oxygenase 2 mRNA, all factors associated with tumour progression and migration, can explain the role of TLR9 
in cancer [73, 74]. At first, CQ was thought to inhibit this pathway by inhibiting endosomal acidification. However, CQ most likely modifies 
the structure of the nucleic acids responsible for TLR activation to prevent binding to TLRs [77]. An in vitro study also showed that invasion 
of brain cancer cells is hypoxia-induced through upregulation of TLR9 expression, which could be significantly inhibited by CQ [78].
In contrast, low expression of TLR9 is reported to be associated with a poorer prognosis in patients with triple-negative breast cancer. CQ 
had a promising effect on tumour growth and invasiveness, independent of the TLR9 status in triple-negative breast cancer cells in vitro, 
but it did not reduce the growth of orthotopic triple-negative breast cancer tumours in vivo [79, 80]. 
Inhibition of CXCL12/CXCR4 signalling
The interaction between the CXCR4 chemokine receptor and its ligand CXCL12 plays a major role in chemotaxis and adhesion of cells, and 
secretion of growth factors. In recent years, research has shown an association between CXCL12/CXCR4 signalling and cancer progres-
sion [81, 82]. This interaction is said to influence the invasive phenotype of pancreatic cancer for example. 
In 2012, a CXCR4 small molecule antagonist (NSC56612), structurally resembling CQ and HCQ, was identified through in silico model-
ling of this receptor [82]. Next, CQ and HCQ were tested via in vitro assays, in which they were found to suppress pancreatic cancer cell 
proliferation [82, 83]. Mechanistic studies have shown that CQ, at least, partially inhibits CXCL12/CXCR4 signalling, as demonstrated 
via reduced phosphorylation of the extracellular signal-regulated kinase (ERK) and the signal transducer and activator of transcription 3 
(STAT3). Interestingly, CQ and HCQ can induce CXCR4 internalisation in cancer stem cells, making these cells less sensitive to CXCL12 
signals [83]. 
Furthermore, a study in a pancreatic cancer patient-derived xenograft model showed that CQ specifically targets highly aggressive cancer 
stem cells through inhibition of their self-renewal process. Thus, CQ could be useful to block cancer stem cell-metastasis and may be com-
bined with other anti-cancer agents (e.g. gemcitabine) that target the bulk of the tumour [83].
Interference with the p53 pathway
The tumour suppressor protein p53 plays an essential role in maintaining an error-free genome and inducing cell death in case the damage 
is irretrievable. Therefore, it is a key protein in the prevention of tumour development [84]. 
Both in vitro and in vivo research has indicated that CQ can stabilise the p53 protein and activate the p53-dependent transcription of pro-
apoptotic genes [17, 23, 24, 72, 84, 85]. Several hypotheses have been proposed to explain the underlying mechanism, but there is no 
definite answer yet. One of these hypotheses is that CQ intercalates in DNA, which leads to structural changes and thus induction of p53 
[17, 85]. Moreover, the p53 activation by CQ might be mediated by the ataxia telangiectasia mutated protein, dependent on the cell type 
[17, 23, 24]
There is also some discussion about the relationship between the p53 status and the effects of autophagy inhibition on cancer develop-
ment. Several studies report an accelerated tumour development when autophagy is inhibited in mice without p53 [35, 86, 87], but Yang 
et al [88] showed that that inhibition of autophagy could still have beneficial effect in p53 mutant tumours. Other studies confirmed that CQ 
exerts anti-cancer effects independent of the p53 pathway and the p53 status [88–90]. Synergy between the p53-dependent and -indepen-
dent mechanisms of CQ is likely [17].
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Recently, a p53-dependent mechanism was reported in which CQ induces tumour suppressor protein Par-4 secretion, triggering paracrine 
apoptosis of cancer cells and inhibition of tumour metastasis. This mechanism involves the CQ-dependent activation of p53 and the sub-
sequent induction of Rab8b, which is necessary for transport of vesicles of Par-4 to the plasma membrane [91].
Moreover, CQ might prevent degradation of a p53-related protein, called Bcl homology-3-only protein p53 upregulated modulator of apop-
tosis (PUMA), as shown in mice studies. CQ increased the levels of PUMA, without affecting p53 in these studies [20, 92]. 
Other potential mechanisms of action
Additional mechanisms have been suggested, but they have not been studied to the same extent and will only be briefly described here.
In recent years, it has become clear that glutaminolysis plays an important role in metabolic processes associated with cancer cell prolif-
eration and survival. Therefore, targeting glutaminolysis could provide novel approaches to improve cancer treatment [93]. It was shown 
that CQ affects glutamate dehydrogenase activity [94–96], which could be a potential mechanism of action in anti-cancer treatment. The 
hypothesis of inhibiting metabolic processes using metformin and CQ is currently being tested in one clinical trial with patients with isoci-
trate dehydrogenase 1 and 2 (IDH1/2)-mutated chondrosarcoma, glioma and intrahepatic cholangiocarcinoma [97].
CQ and HCQ can activate caspase-3 and modulate the Bcl-2/Bax ratio inducing apoptosis in CLL, B-cell CLL and glioblastoma cells [17, 89, 
98–100]. CQ-mediated cell-cycle-arrest and apoptosis was observed in breast cancer cells and was associated with a decrease in protein 
levels/activity of polo-like kinase 1 (Plk-1), ERK1/2 Akt and cell division cycle 25C (CDC25C). The same study described induction of cas-
pase-3-mediated spindle abnormalities and down regulation of the mitochondrial transmembrane potential by CQ [101]. A decreased lung 
cancer cell growth after low CQ concentrations was ascribed to an increased lysosomal volume and a phosphatidylcholine-specific phos-
pholipase C involvement (PC-PLC). Higher CQ concentrations still induce apoptosis and necrosis, but likely via different processes [102].
Moreover, HCQ might affect acetylation status in the N-terminal lysines of histones H3 and H4, thus modulating cell growth and differentia-
tion, as shown in human breast cancer cells [103]. 
In addition, CQ might directly affect Hedgehog signalling. Under normal conditions, this is a quiescent pathway, but activation can cause 
tumorigenesis and maintains cancer stem cells. Anti-cancer treatment options targeting this specific pathway have been explored, but 
this has yielded little results so far [104]. One study suggested that CQ might modulate protein levels of the Hedgehog signalling pathway 
(smoothened, patched and GLI1 proteins) [83]. 
CQ can inhibit hypoxia-stimulated metastasis via modulation of hypoxia-inducible factor 1α (HIF-1α), vascular endothelial growth factor 
(VEGF), and epithelial mesenchymal transition (EMT) as shown in a cholangiocarcinoma cell line [105].
In triple-negative breast cancer, CQ was shown to eliminate cancer stem cells through reduction of the expression of Janus-activated 
kinase 2 and DNA methyl transferase 1 [106] or through induction of mitochondrial dysfunction, subsequently causing oxidative DNA dam-
age and impaired repair of double-stranded DNA breaks [107].
Of note, various studies showed growth inhibition of melanoma cells after CQ administration, but this inhibition was more pronounced in 
pigmented melanoma, which could be ascribed to CQ’s high affinity for melanin [108]. There is also some contradictory evidence about a 
potential link between Burkitt’s lymphoma incidence and CQ administration [109, 110]. 
Modulation of tumour micro-environment
Immunomodulation
An increasing level of research is addressing the essential role of the immune system in cancer development. Activating the immune 
system against cancer cells is becoming a promising therapeutic approach [111], as immune cells have the ability to detect and destroy 
malignant cells [66]. 
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Interestingly, autophagy and lysosomal function have been found to be involved in both innate and adaptive immunity [66]. Therefore, 
inhibitors of these processes such as CQ and HCQ could potentially modulate the immune system and subsequently influence tumour 
development. However, lysosomal function and autophagy have a dual role in the anti-tumour immune response. Activation of these pro-
cesses could both activate and impair the immune response, dependent on the circumstances [66]. In addition, autophagy and lysosomal 
function affect the response of tumour cells to the immune system as well. For example, tumour cell autophagy can generate mediators 
that provoke an immune response via modulation of the tumour cell secretome and surface proteome, but it may also help tumour cells to 
escape the immune system [64, 66].
In general, the interaction between cancer cells and the immune system is complex and further research is warranted to determine when 
CQ or HCQ administration can lead to beneficial effects in the context of anti-tumour immunity [112]. This is particularly important if CQ or 
HCQ would be considered for use in combination with immunomodulation anti-cancer therapies.
Normalisation of the tumour vasculature
The tumour vasculature, responsible for supplying the tumour with nutrients and oxygen, is an important component in the tumour micro-
environment and plays an essential role in tumour cell metastasis [113]. A first therapeutic approach is to destroy blood vessels in order to 
block the nutrient and oxygen supply to the tumour. However, accumulating evidence suggests that improving the highly abnormal tumour 
vessel structure, also called vessel normalisation, is preferred over anti-angiogenic therapy. The benefits of vessel normalisation include 
a decrease in tumour hypoxia, reduced cancer cell intravasation and metastasis, and an increase in chemotherapeutic drug delivery and 
response [114, 115]. 
A recent study showed that CQ normalises tumour vessels, independent of its autophagy inhibitory effect, through reduction of vessel den-
sity and improvement of cell alignment and formation of tight junctions. At the molecular level, CQ alters endosomal Notch1 trafficking and 
signalling in endothelial cells, hereby increasing the quiescent phenotype of the endothelial cells [26, 116]. Of note, systemic CQ adminis-
tration has also been shown to reduce the vascular toxicity of the intratumorally administered, anti-tumour agent Transferrin-CRM107 in in 
vivo glioma models [117]. 
Disruption of the CAF—cancer cell interplay
The final interplay between the tumour and its microenvironment that may be influenced by CQ involves CAFs [118]. Glutamine and caveo-
lin-1 are key players in this autophagy-mediated interplay, in which CAFs and tumour cells support each other through glutamine produc-
tion/secretion and autophagy stimulation. Interestingly, this interplay can be uncoupled through the autophagy inhibitory or lysosomotropic 
activity of CQ, but the exact mechanism should still be clarified [119, 120]. 
Synergism with approved anti-cancer drugs
Existing anti-cancer therapies often induce pro-survival autophagy in cancer cells, which is associated with therapeutic resistance. Because 
of their ability to inhibit autophagy, CQ and HCQ are able to sensitise tumour cells to chemotherapy and radiation. Therefore, these drugs 
are often tested in (pre)clinical research in combination with other anti-cancer therapies. Though, some caution is advised when concomi-
tantly using these antimalarial drugs with other anti-cancer agents because autophagy can also be inhibited in normal cells, which causes 
unwanted toxicity (e.g. nephrotoxicity) [121]. 
CQ-mediated sensitisation to anti-cancer therapy has also been ascribed to autophagy-independent mechanisms. As mentioned earlier, 
chemotherapeutics can reach the tumour site more easily after tumour vessel normalisation [26, 116]. Moreover, CQ can prevent the 
entrapment of protonated chemotherapeutic drugs by buffering the extracellular tumour environment and intracellular acidic spaces [112]. 
For example, CQ can reduce the endosomal sequestration of certain drugs by raising the endosomal pH and, thus, increase their efficacy 
(e.g. doxorubicin, daunorubicin and mitoxantrone) [122–124]. Vezmar et al [125, 126] suggested that CQ influences multidrug resistance 
protein-mediated doxorubicin resistance by binding the multidrug resistance protein.
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Prediction of efficacy in individual patients
Autophagy dependency and metabolic stress levels of tumour cells vary widely depending on the tumour type and progression stage. 
Therefore, reliable measurements to predict tumour sensitivity to autophagy inhibition would be extremely useful for patient selection in 
clinical practice [67]. As mentioned earlier, the status of tumour suppressor p53 can affect CQ efficacy, but other CQ sensitivity indicators 
have been identified as well. 
First, EGFR overexpressing tumour cells, high levels of STAT3 activity, loss of caveolin-1, Akt- and Myc- driven tumour cells, and arginino-
succinate synthetase enzyme deficiency are all associated with a high autophagy dependency and are therefore more sensitive to CQ 
administration [16, 28, 119, 127–129]. Next, there is still discussion about the effect of the oncogenic BRAF (V600E) mutation on autophagy 
dependency of tumour cells [47, 130, 131]. In addition, evidence has shown that autophagy is induced by the tumour suppressor alterna-
tive reading frame, but it should still be clarified whether this is cytotoxic or protective autophagy before we can determine whether CQ 
administration would exert beneficial effects [132]. Moreover, oncogenic Ras, and especially Kras, mutation has also been suggested as an 
indicator of autophagy dependency and susceptibility to CQ [27, 133], but two other studies have reported that this mutation is not a reliable 
indicator [134, 135]. As mentioned earlier, however, HCQ has been shown to promote tumour growth in Ras-driven pancreatic tumours 
developing without p53 (KrasG12D/+ p53–/–) [35, 36]. Cells with the IDH1/2 mutations are metabolically vulnerable to CQ treatment, because 
they depend on glutaminolysis and autophagy, which is inhibited by CQ [97].
Autophagy dependency is higher in case of nutritional stress, as shown in mesothelioma cells [128], and neuroendocrine lung tumour cells 
are more sensitive to autophagy inhibition than non-neuroendocrine lung tumour cells [136].
Finally, an in vitro study in four human glioma cell lines observed that higher steady-state mitochondrial membrane potential values, repre-
senting mitochondrial stability, can predict cancer cell resistance to CQ treatment [137].
Our take
The final goal of this literature review was to inform further research and trials on repurposing CQ and HCQ as anti-cancer agents, as done 
previously for other agents [138]. In addition, the ideal dose, route of administration, and therapeutic schedule that should be applied in 
anti-cancer therapy was explored. Finally, the potential difference in efficacy and toxicity between CQ and HCQ has been investigated. 
Efficacy of CQ and HCQ in anti-cancer therapy
The vast majority of preclinical studies on the effect of CQ monotherapy in cancer have reported a positive therapeutic effect, but the study 
parameters, doses, animal models and tumour types differ strongly between studies, complicating the interpretation of the results. Preclini-
cal studies investigating the effect of HCQ in cancer are limited. Therefore, follow-up in vivo studies are warranted. A risk of publication bias 
exists so we cannot guarantee that all negative results have been reported.
Combination therapy with CQ or HCQ and existing anti-cancer therapies has been extensively studied in preclinical research, both in vitro 
and in vivo. The majority of these studies have reported an improved therapeutic efficacy as compared with monotherapy with existing anti-
cancer drugs. Most studies hypothesise that CQ and HCQ could increase the efficacy of other anti-cancer drugs by blocking pro-survival 
autophagy. Because not all studies measured autophagy levels in vivo, it is difficult to determine to what extent the other proposed mecha-
nisms play a role. Table 2 is limited to studies that tested CQ or HCQ in combination with conventional anti-cancer agents in vivo, but there 
are many other combinations that have only been tested in vitro.
Finally, multiple clinical trials have investigated, or are going to investigate, the use of CQ and HCQ in different cancer types, always in 
combination with other anti-cancer drugs. The availability of clinical results is limited now, as most trials are still recruiting or ongoing, 
and those that have been completed focused primarily on safety and tolerability of CQ and HCQ in cancer. In short, these drugs have 
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been found safe and tolerable in all completed studies and the anti-cancer effect of both compounds is promising. However, as many 
clinical trials are still ongoing, a definite conclusion on the repurposing intent of CQ and HCQ in anti-cancer therapy is pending. Still, 
data from first clinical trials and additional preclinical data point to a potential positive implementation of these drugs in anti-cancer 
treatment.
Doses, route of administration and therapeutic schedule
In preclinical experiments, varying CQ and HCQ doses have been used, but most of the applied doses can be extrapolated to human 
doses. However, whether the dose to achieve autophagy inhibition, induction of apoptosis and tumour normalisation is achievable in 
humans remains an open question that would require collecting additional data in humans [112]. Clinical trials have shown that daily 
doses between 150 and 500 mg for CQ and daily doses between 400 and 1200 mg for HCQ are safe and well tolerated, but two studies 
identified 600-mg HCQ daily as the MTD. HCQ is often administered twice daily to limit plasma fluctuations and toxicity. Of note, Pascolo 
recommended 10 mg/kg as the maximum realistic clinical dosage of CQ, but the recommended dose and MTD of CQ and HCQ might vary 
dependent on the tumour type and the concomitantly administered anti-cancer treatments.
Pascolo also suggests that timing of administration is of great importance. CQ must be administered after chemotherapy and not before, 
which is supported by data in a mouse model of colorectal cancer treated with gemcitabine [139].
CQ or HCQ?
HCQ has been reported to have less side effects than CQ (e.g. less risk of retinal toxicity) [9, 140, 141], so it can be administered in higher 
doses for human use. Currently it is not clear yet whether there are differences in anti-cancer treatment efficacy between CQ and HCQ. The 
clinical trials that have already been completed suggest that CQ might be more efficacious than HCQ. However, no comparative clinical trial 
has been set up to confirm this hypothesis. 
Yet, based on chemical structure, the altered safety and efficacy can be ascribed to the additional hydroxyl group in HCQ, causing pharma-
cokinetic differences that are essential for the working mechanism of the drugs (e.g. pKa alteration leading to differences in biprotonation 
and distribution) [14, 140]. 
Next steps
More than 30 clinical trials are currently ongoing (Feb 2017). The results of these trials may indicate which tumour types are most sensitive 
to CQ and HCQ treatment, and which combination therapies can be beneficial. Additional preclinical studies could further characterise the 
most relevant mechanisms of action and their individual importance in anti-cancer therapy. Finally, CQ analogues and other more specific 
autophagy inhibitory agents are also under investigation for the treatment of cancer patients (e.g. Lys05) [142–146].
Conclusion
CQ and HCQ have been studied in multiple preclinical cancer models and have demonstrated activity on several cancer-supporting path-
ways and in combination with a broad range of other therapies. Our review has highlighted the interesting multi-faceted actions of CQ and 
HCQ against cancer, making these drugs attractive for this complex disease [147, 148].
Even though it is too soon to make definite conclusions about the overall effect of CQ and HCQ in anti-cancer treatments, the clinical 
data already available are encouraging to further explore their potential as anti-cancer agents, with a preference for CQ. Until now, most 
clinical evidence was found in patients with glioblastoma and brain metastases and in patients with BRAF mutations, but some promising 
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effects have been reported in patients with lung cancer, multiple myeloma and sarcoma as well. Although the side effects of CQ and HCQ 
are minor in comparison with conventional anti-cancer therapy, the possibility of retinal toxicity in trials planning long-term CQ and HCQ 
exposure requires the implementation of ophthalmologic monitoring. More than 30 clinical studies are currently evaluating HCQ and CQ 
in different cancers, most of them with the rationale to increase the efficacy of other anti-cancer therapies through inhibition of treatment-
induced autophagy. The first clinical trials with CQ and HCQ have focused on the toxicity of different CQ doses in multiple populations and 
new trials should now focus on rigorous evaluation of efficacy.
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